Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Get Real-Time News and Alerts for Your Portfolio Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...

While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...

Alzheimer’s treatments are a potential $13 billion market by 2030, with major pharma cos investing heavily. Biogen and Eli Lilly have drugs like Leqembi and Kisunla available, but challenges remain.